0001493152-26-021863
SEC filingAIM ImmunoTech Inc. entered into a warrant inducement agreement on May 7, 2026, allowing holders to exercise existing warrants at $0.48 per share for ~$4.20M gross proceeds in exchange for new Class H warrants to purchase 17,439,856 shares at $0.60, subject to stockholder approval.
AIM ImmunoTech Inc. executed a warrant exercise inducement letter on May 7, 2026, targeting holders of existing warrants from May 2024, September 2024, and July 2025 issuances totaling up to 8,719,928 shares. By reducing the exercise price to $0.48 from original levels ($36.30, $28.00, $1.439), the company incentivizes immediate cash exercises yielding approximately $4.20 million in gross proceeds if fully subscribed. In exchange, holders receive new Class H warrants covering 200% of exercised shares, or 17,439,856 shares total, exercisable at $0.60 starting post-stockholder approval with a 5-year term. This structure accelerates cash inflow for working capital while issuing dilutive equity securities, subject to NYSE American stockholder ratification within 75 days of the expected May 8 closing. Ladenburg Thalmann acts as placement agent, earning 8% of proceeds plus warrants for 6% of shares at a premium price, aligning incentives for execution. Inducement warrants were issued unregistered under Section 4(a)(2), with a committed S-3 filing 30 days post-closing to enable resale. The transaction underscores capital-raising urgency amid low warrant exercise prices, potentially increasing outstanding warrants significantly upon approval, impacting future dilution and shareholder base.